The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?

Yiqing Huang, Robert J. Walsh, Ross A. Soo


Immune checkpoint inhibitors (ICIs) have altered the treatment landscape of advanced non-small cell lung cancer (NSCLC) that lack driver mutations. In 2016, Reck and colleagues first reported the superiority of pembrolizumab versus chemotherapy in advanced NSCLC with PD-L1 tumour proportion score (TPS) ≥50% (KEYNOTE 024) (1).